

DAFTAR PUSTAKA

- Abdelmoneim, A.S., Eurich, D.T., Gamble, J.M., Johnson, J.A., Seubert, J.M., Qiu, W., dkk., 2014. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. *Diabetes, Obesity & Metabolism*, 16: 22–29.
- Abdelmoneim, A.S., Hasenbank, S.E., Seubert, J.M., Brocks, D.R., Light, P.E., dan Simpson, S.H., 2012. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. *Diabetes, Obesity and Metabolism*, 14: 130–138.
- American Diabetes Association, 2020. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes 2020. *Diabetes Care*, 43: S98–S110.
- Ashcroft, F.M. dan Rorsman, P., 1989. Electrophysiology of the pancreatic β -cell. *Progress in Biophysics and Molecular Biology*, 54: 87–143.
- Azoulay, L. dan Suissa, S., 2017. Sulfonylureas and the risks of cardiovascular events and death: A methodological meta-regression analysis of the observational studies. *Diabetes Care*, 40: 706–714.
- Baumeister, R.F. dan Leary, M.R., 1997. Writing narrative literature reviews. *Review of General Psychology*, 1: 311–320.
- Bo, S., Castiglione, A., Ghigo, E., Gentile, L., Durazzo, M., Cavallo-Perin, P., dkk., 2013. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. *European journal of endocrinology*, 169: 117–126.
- Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A.M., dkk., 2012. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. *The Journal of Clinical Endocrinology and Metabolism*, 97: 1020–1031.
- Calvert, J.W., Gundewar, S., Jha, S., Greer, J.J.M., Bestermann, W.H., Tian, R., dkk., 2008. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. *Diabetes*, 57: 696–705.
- Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., dkk., 2015. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*, 17: 1180–1193.
- Cho, E.-H., Han, K., Kim, B., dan Lee, D.H., 2020. Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus. *Medicine*, 99: e21236.
- Comoglio, R.H. dan Guitart, X.V., 2020. Cardiovascular events and mortality among type 2 diabetes mellitus patients newly prescribed first-line blood glucose-lowering drugs monotherapies: A population-based cohort study in the Catalan electronic medical record database, SIDIAP, 2010-2015.

Primary care diabetes, 2: 323-331.

- Currie, C.J., Poole, C.D., Evans, M., Peters, J.R., dan Morgan, C.L., 2013. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. *The Journal of clinical endocrinology and metabolism*, 98: 668–677.
- Dörschner, H., Brekardin, E., Uhde, I., Schwanstecher, C., dan Schwanstecher, M., 1999. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. *Molecular Pharmacology*, 55: 1060–1066.
- Douros, A., Dell’Aniello, S., Yu, O.H.Y., Filion, K.B., Azoulay, L., dan Suissa, S., 2018. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. *BMJ (Clinical research ed.)*, 362: k2693.
- Douros, A., Yin, H., Yu, O.H.Y., Filion, K.B., Azoulay, L., dan Suissa, S., 2017. Pharmacologic Differences of Sulfonylureas and The Risk of Adverse Cardiovascular and Hypoglycemic Events. *Diabetes Care*, 40: 1506–1513.
- Einarson, T.R., Acs, A., Ludwig, C., dan Panton, U.H., 2018. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017. *Cardiovascular Diabetology*, 17: 1–19.
- Engler, C., Leo, M., Pfeifer, B., Juchum, M., Chen-Koenig, D., Poelzl, K., dkk., 2020. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018. *BMJ open diabetes research & care*, 8: e001279.
- Eriksson, J.W., Bodegard, J., Nathanson, D., Thuresson, M., Nyström, T., dan Norhammar, A., 2016. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. *Diabetes research and clinical practice*, 117: 39–47.
- Evans, J.M.M., Ogston, S.A., Emslie-Smith, A., dan Morris, A.D., 2006. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. *Diabetologia*, 49: 930–936.
- Faries, P.L., Rohan, D.I., Wyers, M.C., Marin, M.L., Hollier, L.H., Quist, W.C., dkk., 2002. Vascular smooth muscle cells derived from atherosclerotic human arteries exhibit greater adhesion, migration, and proliferation than venous cells. *The Journal of Surgical Research*, 104: 22–28.
- Filion, K.B., Douros, A., Azoulay, L., Yin, H., Yu, O.H., dan Suissa, S., 2019. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. *British journal of clinical pharmacology*, 85: 2378–2389.
- Flagg, T.P., Kurata, H.T., Masia, R., Caputa, G., Magnuson, M.A., Lefer, D.J., dkk., 2008. Differential structure of atrial and ventricular KATP. *Circulation Research*, 103: 1458–1465.
- Forst, T., Hanefeld, M., Jacob, S., Moeser, G., Schwenk, G., Pfützner, A., dkk., 2013. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of

- observational studies. *Diabetes & vascular disease research*, 10: 302–314.
- Ghotbi, A.A., Køber, L., Finer, N., James, W.P.T., Sharma, A.M., Caterson, I., dkk., 2013. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. *Diabetes care*, 36: 3746–3753.
- Groop, L.C., 1992. Sulfonylureas in NIDDM. *Diabetes Care*, 15: 737–754.
- Hausenloy, D.J., Wynne, A.M., Mocanu, M.M., dan Yellon, D.M., 2012. Glimpiride treatment facilitates ischemic preconditioning in the diabetic heart. *Journal of Cardiovascular*, 18: 263–269.
- Hsu, C.-Y., Fang, S.-Y., Chen, Y.-Z., Roan, J.-N., Chang, S.-W., Huang, C.-C., dkk., 2012. Cardiovascular protection of activating KATP channel during ischemia-reperfusion acidosis. *Shock*, 37: 653–658.
- Huang, Y., Abdelmoneim, A.S., Light, P., Qiu, W., dan Simpson, S.H., 2015. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. *Journal of diabetes and its complications*, 29: 196–202.
- Inagaki, N., Gonoi, T., Clement, J.P., Namba, N., Inazawa, J., Gonzalez, G., dkk., 1995. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. *Science*, 270: 1166–1170.
- Inagaki, N., Gonoi, T., Iv, J.P.C., Wang, C.-Z., Aguilar-Bryan, L., Bryan, J., dkk., 1996. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K⁺ channels. *Neuron*, 16: 1011–1017.
- Ioacara, S., Guja, C., Georgescu, O., Martin, S., Sirbu, A., Purcaru, M., dkk., 2017. Patients treated with insulin and sulphonylurea are at increased mortality risk as compared with those treated with insulin plus metformin. *Acta endocrinologica*, 13: 329–333.
- Irie, H., Gao, J., Gaudette, G.R., Cohen, I.S., Mathias, R.T., Saltman, A.E., dkk., 2003. Both metabolic inhibition and mitochondrial KATP channel opening are myoprotective and initiate a compensatory sarcolemmal outward membrane current. *Circulation*, 108: 341–347.
- Khalangot, M., Tronko, M., Kravchenko, V., dan Kovtun, V., 2009. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. *Diabetes research and clinical practice*, 86: 247–253.
- Krentz, A.J. dan Bailey, C.J., 2005. Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus. *Drugs*, 65: 385–411.
- Lawrence, C.L., Proks, P., Rodrigo, G.C., Jones, P., Hayabuchi, Y., Standen, N.B., dkk., 2001. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. *Diabetologia*, 44: 1019–1025.
- Lawrence, C.L., Rainbow, R.D., Davies, N.W., dan Standen, N.B., 2002. Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels. *British journal of pharmacology*, 136: 746–752.
- Lederer, W.J., Nichols, C.G., dan Smith, G.L., 1989. The mechanism of early contractile failure of isolated rat ventricular myocytes subjected to complete

- metabolic inhibition. *The Journal of Physiology*, 413: 329–349.
- Lee, Y.-C., Chang, C.-H., Dong, Y.-H., Lin, J.-W., Wu, L.-C., Hwang, J.-S., dkk., 2017. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study. *International journal of cardiology*, 228: 1007–1014.
- Leon, B.M. dan Maddox, T.M., 2015. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. *World Journal of Diabetes*, 6: 1246–1258.
- Li, Y., Hu, Y., Ley, S.H., Rajpathak, S., dan Hu, F.B., 2014. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. *Diabetes care*, 37: 3106–3113.
- Low Wang, C.C., Hess, C.N., Hiatt, W.R., dan Goldfine, A.B., 2016. Clinical update: cardiovascular disease in diabetes mellitus. *Circulation*, 133: 2459–2502.
- Meinert, C.L., Knatterud, G.L., Prout, T.E., dan Klimt, C.R., 1970. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. *Diabetes*, 19: Suppl:789-830.
- Mellbin, L.G., Malmberg, K., Norhammar, A., Wedel, H., dan Rydén, L., 2008. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. *European heart journal*, 29: 166–176.
- Mocanu, M.M., Maddock, H.L., Baxter, G.F., Lawrence, C.L., Standen, N.B., dan Yellon, D.M., 2001. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. *Circulation*, 103: 3111–3116.
- Mogensen, U.M., Andersson, C., Fosbøl, E.L., Schramm, T.K., Vaag, A., Scheller, N.M., dkk., 2015. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality-a retrospective nationwide study. *Diabetes research and clinical practice*, 107: 104–112.
- Monami, M., Genovese, S., dan Mannucci, E., 2013. Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials. *Diabetes Obesity and Metabolism*, 15: 938–953.
- Morales, J. dan Schneider, D., 2014. Hypoglycemia. *American Journal of Medicine*, 127: S17–S24.
- Murry, C.E., Jennings, R.B., dan Reimer, K.A., 1986. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation*, 74: 1124–1136.
- Nakaya, H., Y., T., Tohse, N., dan Kanno, M., 1991. Effects of ATP-sensitive K⁺ channel blockers on the action potential shortening in hypoxic and ischaemic myocardium. *Br J Pharmacol*, 103: 1019–1026.
- Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondy, N., dkk., 2017. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *New England Journal of Medicine*, 377: 644–657.
- Negroni, J.A., Lascano, E.C., dan del Valle, H.F., 2007. Glibenclamide action on myocardial function and arrhythmia incidence in the healthy and diabetic

- heart. *Cardiovascular & hematological agents in medicinal chemistry*, 5: 43–53.
- Ou, H.-T., Chang, K.-C., Li, C.-Y., dan Wu, J.-S., 2016. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study. *Cardiovascular diabetology*, 15: 41.
- Pachiappan, S., Sukumaran, A., Mathew, S., Varghese, S., dan Aloysious, T., 2018. Effect of diabetic medication on cardiovascular risk and microvascular complication in diabetic patients: retrospective cohort study. *Journal of Applied Pharmaceutical Science*, 8: 31–36.
- Powers, A.C. dan D'Alessio, D., 2011. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia, dalam: Brunton, L.L., Chabner, B.A., dan Knollmann, B.C. (Editor), *Goodman & Gilman's: The Pharmacological Basis of Therapeutics*. McGraw-Hill, New York, hal. 1255–1257.
- Proks, P., Reimann, F., Green, N., Gribble, F., dan Ashcroft, F., 2002. Sulfonylurea stimulation of insulin secretion. *Diabetes*, 51: S368–S376.
- Quianzon, C.C.L. dan Cheikh, I.E., 2012. History of current non-insulin medications for diabetes mellitus. *Journal of Community Hospital Internal Medicine Perspectives*, 2: 3.
- Rados, D.V., Pinto, L.C., Remonti, L.R., Leitão, C.B., dan Gross, J.L., 2016. The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. *PLoS medicine*, 13: e1001992.
- Rendell, M., 2004. The role of sulphonylureas in the management of type 2 diabetes mellitus. *Drugs*, 64: 1339–1358.
- Roumie, C.L., Hung, A.M., Greevy, R.A., Grijalva, C.G., Liu, X., Murff, H.J., dkk., 2012. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. *Annals of internal medicine*, 157: 601–610.
- Roumie, C.L., Min, J.Y., D'Agostino McGowan, L., Presley, C., Grijalva, C.G., Hackstadt, A.J., dkk., 2017. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: A cohort study. *Journal of the American Heart Association*, 6: e005379.
- Sarwar, N., Gao, P., Seshasai, S.R.K., Gobin, R., Kaptoge, S., Di Angelantonio, E., dkk., 2010. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*, 375: 2215–2222.
- Schramm, T.K., Gislason, G.H., Vaag, A., Rasmussen, J.N., Folke, F., Hansen, M.L., dkk., 2011. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. *European heart journal*, 32: 1900–1908.
- Seong, J.-M., Choi, N.-K., Shin, J.-Y., Chang, Y., Kim, Y.-J., Lee, J., dkk., 2015. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin,

- for type 2 diabetes: a population-based cohort study. *PloS one*, 10: e0124287.
- Simpson, S.H., Majumdar, S.R., Tsuyuki, R.T., Eurich, D.T., dan Johnson, J.A., 2006. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. *Canadian Medical Association Journal*, 174: 169–174.
- Singh, S., Singh, H., Singh, P.P., Murad, M.H., dan Limburg, P.J., 2013. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: A systematic review and meta-analysis. *Cancer Epidemiology Biomarkers and Prevention*, 22: 2258–2268.
- Skillman, T.G. dan Feldman, J.M., 1981. The pharmacology of sulfonylureas. *The American Journal of Medicine*, 70: 361–372.
- Sola, D., Rossi, L., Schianca, G.P.C., Maffioli, P., Bigliocca, M., Mella, R., dkk., 2015. Sulfonylureas and their use in clinical practice. *Archives of Medical Science*, 11: 840-848.
- Solini, A., Giannini, L., Seghieri, M., Vitolo, E., Taddei, S., Ghiadoni, L., dkk., 2017. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. *Cardiovascular Diabetology*, 16: 138.
- Solymár, M., Ivic, I., Póto, L., Hegyi, P., Garami, A., Hartmann, P., dkk., 2018. Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis. *PloS One*, 13: e0207947.
- Stanley, W.C., 2004. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. *Journal of Cardiovascular Pharmacology and Therapeutics*, 9 Suppl 1: S31-45.
- Sullivan, D., Forder, P., Simes, J., Whiting, M., Kritharides, L., Merrifield, A., dkk., 2011. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. *Diabetes research and clinical practice*, 94: 284–290.
- Triplitt, C.L., Reasner, C.A., dan Isley, W.L., 2005. Diabetes Mellitus, dalam: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., dan Posey, L.M. (Editor), *Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill, New York, hal. 1347–1349.
- Ugwoke, C.K., Slokar, U., Nakayama, A., dan Umek, N., 2017. Sulfonylureas in type 2 diabetes mellitus: Current evidence, conflicts and clinical implications. *Nigerian Journal of Medicine*, 26: 68.
- Van Gaal, L. dan Scheen, A., 2015. Weight management in type 2 diabetes: current and emerging approaches to treatment. *Diabetes Care*, 38: 1161–1172.
- Venkatesh, N., Lamp, S.T., dan Weiss, J.N., 1991. Sulfonylureas, ATP-sensitive K⁺ channels, and cellular K⁺ loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. *Circulation Research*, 69: 623–637.
- Wakiyama, H., Cowan, D.B., Toyoda, Y., Federman, M., Levitsky, S., dan McCully, J.D., 2002. Selective opening of mitochondrial ATP-sensitive potassium channels during surgically induced myocardial ischemia decreases necrosis and apoptosis. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic*

- Surgery*, 21: 424–433.
- Wilke, T., Mueller, S., Groth, A., Berg, B., Hammar, N., Tsai, K., dkk., 2015. Effectiveness of sulphonylureas in the therapy of diabetes mellitus type 2 patients: an observational cohort study. *Journal of diabetes and metabolic disorders*, 15: 28.
- Wing, R.R., Lang, W., Wadden, T.A., Safford, M., Knowler, W.C., Bertoni, A.G., dkk., 2011. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care*, 34: 1481–1486.
- Xu, M., Wang, Y., Ayub, A., dan Ashraf, M., 2001. Mitochondrial KATP channel activation reduces anoxic injury by restoring mitochondrial membrane potential. *Am J Physiol Heart Circ Physiol*, 281: 1295–1303.
- Yamada, M., Isomoto, S., Matsumoto, S., Kondo, C., Shindo, T., Horio, Y., dkk., 1997. Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K⁺ channel. *The Journal of Physiology*, 499: 715–720.
- Yang, D., Sun, C., Zhang, J., Lin, S., Zhao, L., Wang, L., dkk., 2018. Proliferation of vascular smooth muscle cells under inflammation is regulated by NF- κ B p65/microRNA-17/RB pathway activation. *International Journal of Molecular Medicine*, 41: 43–50.
- Zhang, R., Zou, Z., Zhou, X., Shen, X., Fan, Z., Xie, T., dkk., 2019. Comparative effects of three sulfonylureas (glibenclamide, glimepiride, and gliclazide) on proliferation and migration of vascular smooth muscle cells. *Cellular Physiology and Biochemistry*, 52: 16–26.
- Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., dkk., 2015. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *New England Journal of Medicine*, 373: 2117–2128.